China Resources Double-Crane Pharmaceutical Co.,Ltd. — Investor Relations & Filings
About China Resources Double-Crane Pharmaceutical Co.,Ltd.
China Resources Double-Crane Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of a diverse range of pharmaceutical products. The company maintains a significant market presence in several therapeutic areas, including cardiovascular health, endocrinology, pediatrics, and nephrology. It is recognized as a leading provider of large-volume parenteral solutions and chronic disease management medications. Its product portfolio features essential medicines such as antihypertensives, oral hypoglycemic agents, and specialized nutritional supports. Leveraging advanced manufacturing facilities and a robust research and development infrastructure, the company focuses on delivering high-quality healthcare solutions. The organization operates with a commitment to technological innovation and quality control, serving a broad network of medical institutions and healthcare providers.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 华润双鹤关于公司2021年限制性股票激励计划首次授予部分第三个解除限售期解锁暨限制性股票上市公告 | 2026-04-14 | Chinese | |
| 华润双鹤2025年度内部控制评价报告 | 2026-03-19 | Chinese | |
| 华润双鹤2025年度可持续发展报告 | 2026-03-19 | Chinese | |
| 华润双鹤董事会审计与风险管理委员会对会计师事务所履行监督职责情况报告 | 2026-03-19 | Chinese | |
| 华润双鹤2025年年度报告摘要 | 2026-03-19 | Chinese | |
| 毕马威华振：关于华润双鹤2025年度非经营性资金占用及其他关联资金往来情况的专项说明 | 2026-03-19 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 34900836 | 华润双鹤关于公司2021年限制性股票激励计划首次授予部分第三个解除限售期解锁暨限制性股票上市公告 | 2026-04-14 | Chinese | ||
| 40269049 | 华润双鹤2025年度内部控制评价报告 | 2026-03-19 | Chinese | ||
| 40269040 | 华润双鹤2025年度可持续发展报告 | 2026-03-19 | Chinese | ||
| 40268716 | 华润双鹤董事会审计与风险管理委员会对会计师事务所履行监督职责情况报告 | 2026-03-19 | Chinese | ||
| 40268715 | 华润双鹤2025年年度报告摘要 | 2026-03-19 | Chinese | ||
| 40268713 | 毕马威华振：关于华润双鹤2025年度非经营性资金占用及其他关联资金往来情况的专项说明 | 2026-03-19 | Chinese | ||
| 40268650 | 华润双鹤关于2025年度利润分配方案公告 | 2026-03-19 | Chinese | ||
| 40268644 | 华润双鹤2025年度审计与风险管理委员会履职报告 | 2026-03-19 | Chinese | ||
| 40268637 | 华润双鹤关于2025年度“提质增效重回报”行动方案评估报告及2026年度“提质增效重回报”行动方案的公告 | 2026-03-19 | Chinese | ||
| 40268632 | 毕马威华振：华润双鹤2025年度内部控制审计报告 | 2026-03-19 | Chinese | ||
| 40268615 | 华润双鹤关于变更注册资本及修订公司《章程》的公告 | 2026-03-19 | Chinese | ||
| 40268607 | 华润双鹤关于控股子公司湖南省湘中制药有限公司丙戊酸钠口服溶液获得药品注册证书的公告 | 2026-03-17 | Chinese | ||
| 40268600 | 华润双鹤关于召开2025年度业绩说明会的公告 | 2026-03-12 | Chinese | ||
| 40268587 | 华润双鹤关于2021年限制性股票激励计划回购注销实施公告 | 2026-03-11 | Chinese | ||
| 40268581 | 北京市中伦律师事务所关于华润双鹤药业股份有限公司2021年限制性股票激励计划部分限制性股票回购注销实施的法律意见书 | 2026-03-11 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
China Resources Double-Crane Pharmaceutical Co.,Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/56457/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=56457 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=56457 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=56457 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 56457}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for China Resources Double-Crane Pharmaceutical Co.,Ltd. (id: 56457)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.